Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI™ (lifileucel) for Advanced Melanoma

Published

on

wuxi-advanced-therapies-receives-fda-approval-to-manufacture-iovance’s-amtagvi™-(lifileucel)-for-advanced-melanoma

AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer.

PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ — WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.

AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. AMTAGVI is also the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer.

With this announcement, WuXi ATU’s Philadelphia site becomes the first U.S. external manufacturing site and the first third-party contract testing, development, and manufacturing organization (CTDMO) to be approved by the FDA to support the commercial manufacturing and release of an individualized T cell therapy for a solid tumor cancer.

“We congratulate Iovance on this major milestone in their quest to address unmet patient needs in the treatment of advanced melanoma. WuXi ATU has partnered with Iovance since 2015, and we are thrilled to help them through each step of the drug development pipeline – from research to clinical manufacturing to FDA approval,” said Edward Hu, Chief Executive Officer of WuXi ATU and Vice Chairman of WuXi AppTec. “We are proud of our track record of enabling healthcare innovators to advance medical discoveries and deliver groundbreaking treatments to patients globally.” 

Iovance, (NASDAQ: IOVA) is headquartered in San Carlos, California with an FDA-approved built-to-suit custom manufacturing facility, the Iovance Cell Therapy Center (iCTC), adjacent to WuXi ATU in the Navy Yard Philadelphia. The company is committed to innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies, including gene-edited cell therapies, for patients with cancer.

“The accelerated approval of AMTAGVI™ is the first step in realizing Iovance’s ambition to usher in the next generation of cell therapy by bringing this breakthrough to patients with advanced solid tumors,” said Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President of Iovance. “Given the significant unmet needs in the advanced melanoma community, we are proud to offer a personalized, one-time therapeutic option for these patients. WuXi ATU has partnered with us to manufacture this cell therapy for close to a decade. It is a great benefit to both Iovance and the healthcare community to have a contract testing, development, and manufacturing partner adjacent to our facilities. Working together, our teams can make a meaningful difference for patients.”

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s AMTAGVI™  is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer. For more information, please visit www.iovance.com.

About WuXi Advanced Therapies (WuXi ATU)

Advertisement

As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers advanced platforms and end-to-end solutions that enable the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world. For more information visit www.advancedtherapies.com

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”

CONTACTS

WuXi Advanced Therapies 
Amy Lamperti
Executive Director, Global Marketing
215-218-7100
[email protected] 

WuXi AppTec
Davy Wu
Executive Director, Brand & Corporate Communications
[email protected]

Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations & Corporate Communications
650-260-7120 ext. 264
[email protected]

Jen Saunders
Director, Investor Relations & Public Relations
267-485-3119
[email protected]

Photo – https://mma.prnewswire.com/media/2343218/WuXi_Advanced_Therapies.jpg

Cision View original content:https://www.prnewswire.com/news-releases/wuxi-advanced-therapies-receives-fda-approval-to-manufacture-iovances-amtagvi-lifileucel-for-advanced-melanoma-302065809.html

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

DayOne Launches as an Independent Global Data Center Pioneer Following Series B Funding Closure

Published

on

dayone-launches-as-an-independent-global-data-center-pioneer-following-series-b-funding-closure

SINGAPORE, Dec. 31, 2024 /PRNewswire/ — DayOne, a leading global data center pioneer, officially launched as an independent group on January 1, 2025, ushering in a transformative new era following the successful completion of its series B funding, led by renowned global investment institutions. Formerly operating as GDS International (GDSI), DayOne, founded in 2022 and headquartered in Singapore, has built a proven track record of creating and scaling markets across Asia-Pacific and beyond, driving digital transformation and enhancing regional connectivity.

The brand name “DayOne” encapsulates the company’s entrepreneurial spirit and relentless focus on customers, innovation, and growth. It signifies a mindset of respecting each day as an opportunity to embrace new possibilities, create impactful solutions, and deliver value across the markets we operate in. Inspired by its legacy of pioneering digital infrastructure and unlocking markets, “DayOne” represents a forward-looking commitment to empowering industry leaders with next-generation infrastructure solutions. Guided by humility and a deep reverence for our work and the industries we serve, “DayOne” is dedicated to creating value for all—spanning customers, business partners, investors, employees, and the communities we support.

Over the past year, DayOne secured approximately USD $1.9 billion through its Series A and Series B equity rounds, backed by world-class investors such as SoftBank Vision Fund, Kenneth Griffin, CEO of Citadel, Coatue Management, and Baupost Group.

These investments have not only underscored confidence in DayOne’s ability to deliver reliable, scalable, and sustainable digital infrastructure solutions but have also paved the way for its transformation into an autonomous entity. DayOne’s autonomy spans corporate governance, operations, finance, and technology functions. Its governance is further strengthened by a globally experienced and diverse board, with over half comprising independent investor directors.

Adding to its strategic depth, DayOne recently welcomed three esteemed board leaders: Lim Ah Doo, Co-Chairman of the Board and Chairman of Olam Group Limited; and board advisors Ken Miyauchi, former President & CEO of SoftBank Corp., and Bob McCooey, Vice Chairman of Nasdaq. This robust governance framework ensures balanced decision-making aligned with international best practices, laying a solid foundation for sustainable growth and long-term value creation.        

“The trust from our investors speaks volumes about the strength of DayOne’s vision and our ability to deliver transformative results in a rapidly evolving industry,” said William Huang, Chairman of DayOne. “This transformation goes beyond operational independence— it solidifies our role as a leader in setting new industry benchmarks, advancing regional digital growth, and championing sustainable innovation.”

Jamie Khoo, CEO of DayOne, said: “DayOne represents more than a new name—it’s a commitment to leading with purpose, agility, and innovation. Our focus is on delivering cutting-edge digital infrastructure that propels industries and communities forward. This new chapter empowers us to create lasting impacts on economies and build a future-ready digital ecosystem.”

Gary Wojtaszek, Vice-Chairman of the Board and former President and CEO of CyrusOne, stated: “The formation of DayOne marks a pivotal moment for the industry. Backed by a forward-thinking board and an exceptional leadership team, DayOne is set to redefine digital infrastructure and establish new benchmarks in the sector.”

Operating across key markets such as Singapore, Johor (Malaysia), Batam (Indonesia), Greater Bangkok, Hong Kong SAR, and Tokyo, DayOne combines deep local expertise with a global vision to meet the growing demands of hyperscalers and enterprises. Its innovative strategies, such as the SIJORI market creation, integrate the strengths of Singapore, Johor, and Batam to deliver interconnected, scalable, low-latency, and sustainable digital infrastructure solutions.

DayOne’s competitive edge lies in its ability to anticipate market demands and deliver customer-centric solutions. With a focus on innovation, the company consistently sets industry benchmarks in speed, scalability, and execution. Its sustainability efforts include cutting-edge cooling technologies, renewable energy adoption, and green building designs aimed at reducing environmental impact and enhancing operational resilience.

Advertisement

Looking ahead, DayOne envisions a future where digital infrastructure fuels economic transformation and accelerates global connectivity. By integrating sustainability with advanced technology, DayOne is poised to drive innovation and empower industries worldwide.

About DayOne

DayOne is a data center pioneer that develops and operates next-gen digital infrastructure for industry leaders who demand reliable, cost-effective and quickly scalable solutions.

Our cutting-edge facilities empower hyperscalers and large enterprises to achieve rapid deployment and enhance connectivity, driving transformative engagement and innovation as we shape the future of industries. DayOne’s data centers are located across key markets, including Singapore, Johor (Malaysia), Batam (Indonesia), Greater Bangkok, Hong Kong SAR, Tokyo, and beyond.

Headquartered in Singapore, DayOne’s leadership team draws on over two decades of industry experience and a track record of building Asia’s largest data center business. With DayOne, they have created the SIJORI (Singapore, Johor, and Riau Islands) market as a global data center hub.

As demand for strategically located and customized data centers rises, DayOne’s entrepreneurial spirit, customer-first strategy, deep local partnerships, and agile executional capabilities uniquely position us to power the growth ambitions of leading hyperscalers and large enterprises around the world.

Logo – https://mma.prnewswire.com/media/2588144/5093237/DayOne_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/dayone-launches-as-an-independent-global-data-center-pioneer-following-series-b-funding-closure-302340669.html

Continue Reading

Fintech PR

GES Completes Sale to Truelink Capital

Published

on

ges-completes-sale-to-truelink-capital

Partnership Strengthens Commitment to Growth and Innovation

LAS VEGAS, Dec. 31, 2024 /PRNewswire/ — GES, a global leader in the exhibition and event industry, announced the completion of its sale by Viad Corp to Truelink Capital, a Los Angeles based private equity firm.  This transformational transaction positions GES to accelerate growth as a privately-owned, stand-alone company within Truelink’s portfolio.

“We are thrilled to open a new chapter of our business in 2025 alongside Truelink,” shared Derek Linde, GES Chief Executive Officer. “Our talented team delivered extraordinary event experiences for our clients across the globe during 2024, as we continued to see strong momentum in our business. We are energized by this opportunity to partner with the Truelink team to accelerate innovation and expand our industry-leading capability to deliver premier experiential events to clients worldwide.”

With over 2,600 talented team members and strong, lasting relationships with business partners across the globe, GES and its companies have a decades-long history supporting the world’s leading brands and events in robust business verticals including healthcare, aerospace & defense, financial services, manufacturing, technology, and retail, in a variety of exhibitions, event and experiential marketing capacities.

“Truelink is excited to collaborate with Derek and his leadership team to enhance GES’ position as an industry leader and strengthen the company’s heritage of success,” said Luke Myers, Co-Founder and Managing Partner of Truelink. “We are excited to drive strategic investments to bolster GES and Spiro’s strengths in creative design, logistics and event production, accelerate its tech-enabled offerings, and expand GES’ international reach on Day 1. We thank Viad for its exceptional stewardship and support during the transition period, and look forward to collaborating with the GES leadership team to help the business reach its maximum potential”

About GES:
GES is a leading global provider of exhibition and experiential marketing services to event organizers and brand marketers.  We empower clients to engage their audiences and elevate the customer experience by delivering comprehensive exhibition, experiential, strategic, creative, event management and accommodation, meeting planning and logistical solutions, as well as registration and engagement solutions. GES includes a dynamic collective of industry-leading companies and their distinctive specialties — GES Exhibitions, Spiro, onPeak, SHOWTECH and Visit.  Whether partnering together or working independently, our companies strategically partner with brands and event organizers to transform business objectives into extraordinary experiences that drive meaningful customer connections and bottom-line impact. 

www.ges.com
www.thisisspiro.com
www.onpeak.com
www.showtech.ca
www.visitcloud.com

About Truelink Capital
Truelink Capital is a middle-market private equity firm based in Los Angeles. Truelink pairs deep industry experience in the industrials and technology-enabled services sectors with a commitment to building partnerships that drive long-term value through an operationally focused strategy. Truelink partners with management, corporate sellers, and founders to accelerate growth through the execution of strategic initiatives and transformative add-on acquisitions.

Contacts: 
Marianne Szczech
[email protected]

Photo – https://mma.prnewswire.com/media/2588368/GES_Collective_All_PR_Newswire_1280x960.jpg

Advertisement

Cision View original content:https://www.prnewswire.co.uk/news-releases/ges-completes-sale-to-truelink-capital-302339962.html

Continue Reading

Fintech PR

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60

Published

on

innocan-pharma-announces-closing-of-private-placement-for-gross-proceeds-of-c$635,444.60

NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

HERZLIYA, Israel and CALGARY, AB, Dec. 31, 2024 /PRNewswire/ — Innocan Pharma Corporation (the “Company“) (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the “Offering“) of units of the Company (the “Units“), pursuant to which the Company issued 3,177,223 Units at a price of C$0.20 per Unit (the “Offering Price“) for aggregate gross proceeds of $635,444.60

 

 

Each Unit is comprised of one common share of the Company (a “Common Share“) and one common share purchase warrant of the Company (a “Warrant“). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of C$0.28 for a period of four (4) years from the date of issuance.

The Company paid an arm’s length finder a cash fee of C$13,500 and issued to the finder 67,500 warrants attributable to investors introduced to the Company by the finder within 3 months following such introduction (“Finder Warrants“). Each Finder Warrant entitles the Finder to purchase one Common Share at an exercise price of C$0.28 for a period of four (4) years from the date of issuance.

Iris Bincovich Innocan Pharma’s CEO stated: “I am thrilled with this successful closing of this private placement round, which reflects strong investor confidence in Innocan’s long-term vision, strategic direction as well as our proprietary CBD-loaded liposome platform technology (LPT) and our strongly growing consumer wellness operations. These new funds raised will allow us to further advance our innovative LPT through its regulatory milestones, and furthers our long-term goal of enhancing health and wellness worldwide.”

The Company intends to use the proceeds from the Offering for working capital and general corporate purposes.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act“) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Innocan

Advertisement

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd. which focuses on advanced, targeted online sales.

www.innocanpharma.com 

For further information, please contact:

Iris Bincovich, CEO

+1-516-210-4025
+972-54-3012842
+44 203 769 9377

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Disclaimer for Forward-Looking Information

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts are forward-looking statements. Such forward-looking statements and forward-looking information specifically include, but are not limited to, statements that relate to the use of proceeds of the Offering; and statements regarding the FDA approval process for the Company’s LPT for its human pharmaceutical applications.

Statements contained in this release that are not historical facts are forward-looking statements that involve various risks and uncertainty affecting the business of the Company. Such statements can generally, but not always, be identified by words such as “expects”, “plans”, “anticipates”, “intends”, “estimates”, “forecasts”, “schedules”, “prepares”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. All statements that describe the Company’s plans relating to operations and potential strategic opportunities are forward-looking statements under applicable securities laws. These statements address future events and conditions and are reliant on assumptions made by the Company’s management, and so involve inherent risks and uncertainties, as disclosed in the Company’s periodic filings with Canadian securities regulators. As a result of these risks and uncertainties, and the assumptions underlying the forward-looking information, actual results could materially differ from those currently projected, and there is no representation by the Company that the actual results realized in the future will be the same in whole or in part as those presented herein. The Company disclaims any intent or obligation to update forward-looking statements or information except as required by law. Readers are referred to the additional information regarding the Company’s business contained in the Company’s reports filed with the securities regulatory authorities in Canada. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that could cause actions, events or results not to be as anticipated, estimated or intended. For more information on the Company and the risks and challenges of its business, investors should review the Company’s filings that are available at www.sedarplus.ca.

Advertisement

The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law.

Logo: https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-for-gross-proceeds-of-c635-444-60–302340657.html

Continue Reading

Trending